[{"i":1,"t":"封面","kicker":"","h2":"","sub":"","ds":"","meta":"汇报人： 日期： 覆盖 ①半年度汇报人员提炼 ②Q3 飞书活动与客诉 ③关键客诉与风险 ④ERP 同比（2026 1–9月）⑤主要竞品品牌与优势","eyebrow":"BIORI BIOTECH ｜ 营销中心","tocg":"","h1":"2026 三季度汇报数据汇总","notes":[],"kpis":[],"tables":[],"ids":{}},{"i":2,"t":"目录","kicker":"CONTENTS","h2":"汇报内容","sub":"五章数据 + 附录；全部数字来自 _汇总/*.json，可逐项回溯到飞书原文或 ERP 导出","ds":"22 人/份目标达成、问题、下半年计划与所需支持","meta":"","eyebrow":"","tocg":"01半年度汇报 · 人员提炼22 人/份目标达成、问题、下半年计划与所需支持02Q3 飞书活动与客诉5,584 条活动 / 24 人；活动量不等于产出03关键客诉与风险事项66 条客诉 · 62 条未闭环 · 高风险账款 12 项04ERP 同比2026 年 1–9 月 3,443.0 万，同比 +25.2%05主要竞争对手37 个品牌；诺唯赞 631 次提及，断层第一附录数据源与口径口径自校验与数据缺口说明","h1":"","notes":["本 deck 为数据汇总版：只陈述可溯源事实与数字，不含对策承诺；所有金额口径见末页附录。"],"kpis":[],"tables":[],"ids":{}},{"i":3,"t":"一页摘要","kicker":"EXECUTIVE SUMMARY","h2":"一页摘要","sub":"五项任务的核心结果","ds":"","meta":"","eyebrow":"","tocg":"","h1":"","notes":[],"kpis":["① 半年度汇报22人/份34 份原始件全部转写提炼（含管理 5、说明书 2）","② Q3 飞书活动5,584条24 人 · 7月 1475 ｜ 8月 2016 ｜ 9月 2093","② Q3 客诉66条全量 362；未闭环 62 条（93.9%）","④ ERP 2026 1–9月3,443.0万同比 +25.2%（2025 同期 2749.3 万）","⑤ 竞品品牌37个诺唯赞 631 次提及（占全部命中 49.6%）","③ 高风险账款12项含账龄 365 天以上、逾期 734–895 天"],"tables":[],"ids":{}},{"i":4,"t":"半年度汇报 · 人员提炼","kicker":"","h2":"半年度汇报 · 人员提炼","sub":"","ds":"22 人/份目标达成、问题、下半年计划与所需支持","meta":"","eyebrow":"","tocg":"","h1":"","notes":[],"kpis":[],"tables":[],"ids":{}},{"i":5,"t":"① 人员目标达成总表","kicker":"① 半年度汇报","h2":"人员目标达成总表","sub":"共 22 人（含管理）；达成率按各人自报半年度目标 / 实际计算，未做任何换算或估算","ds":"","meta":"","eyebrow":"","tocg":"","h1":"","notes":["判定档：健康 ≥70% ｜ 关注 50–70% ｜ 警示 20–50% ｜ 严重 <20%。 标「—」者原表未填数（见末页数据缺口）。","⚠ 勾稽提示（原稿自相矛盾，未做修正）：刘新元：目标 6,950.0 万 / 自报完成率 32.5%，但按已填数复算为 31.12%（反推目标约 6,654.8 万）；吴云：目标 3,000.0 万 / 自报完成率 5.3%，但按已填数复算为 0.53%（反推目标约 302.5 万）"],"kpis":[],"tables":[{"h3":"","rows":[["#","姓名","部门 / 区域","半年目标(万)","实际(万)","达成率","进度","判定"],["1","路要峰","诊断原料销售部（原文未标注区域）","200.0","152.4","76.2%","","健康"],["2","刘虹晶","诊断原料销售部（天津、青岛、山东、河北）","340.0","244.3","71.8%","","健康"],["3","李江辉","诊断原料销售部-华中区域","270.0","168.4","62.4%","","关注"],["4","杨天雄","诊断原料销售部（华东/浙江、天津、宁波）","250.0","107.7","43.1%","","警示"],["5","宋学伟","诊断原料销售部（江苏/苏州）","250.0","107.8","42.3%","","警示"],["6","刘欣","销售拓展部","3400.0","1354.0","39.8%","","警示"],["7","冯贤平","诊断原料销售拓展部（北京、京津冀）","220.0","77.8","35.0%","","警示"],["8","刘新元","诊断原料销售部（整体：大客户部+销售拓展部+生命科学销售部）","6950.0","2162.8","32.5% ⚠","","警示"],["9","陈溪子","诊断原料销售部（广州片区＋成都重庆区域）","680.0","217.0","31.9%","","警示"],["10","黄文才","广州、福建","500.0","134.7","26.9%","","警示"],["11","林潇","深圳","270.0","65.7","24.3%","","警示"],["12","赵云浩","诊断原料大客户销售部（圣湘、明德、安图、明日达、万孚 ＋河南","1350.0","282.0","20.9%","","警示"],["13","叶信福","生命科学销售部（科研-浙江）","30.0","5.9","19.6%","","严重"],["14","张文蝶","销售拓展部（上海）","100.0","18.0","18.0%","","严重"],["15","徐卓凡","销售拓展部（上海区域）","100.0","8.3","8.3%","","严重"],["16","吴云","生命科学销售部-浙江","3000.0","16.0","5.3% ⚠","","严重"],["17","王诗香","生命科学销售部（科研-珠海/华南农大）","35.0","1.2","3.5%","","严重"],["18","黄建华","生命科学销售部（科研-广州/中大系）","120.0","2.9","2.5%","","严重"],["19","韩远怀","华南广东销售部","600.0","7.7","1.2%","","严重"],["20","刘斌","生命科学销售部（科研-暨南大学）","—","—","—","","原表未填"],["21","袁殿果","生命科学销售部（科研-浙江/温州）","—","—","—","","原表未填"],["22","侯海瑜","生命科学销售部（科研-浙江/杭州）","—","—","—","","原表未填"]]}],"ids":{}},{"i":6,"t":"① 达成率分布与断层","kicker":"① 半年度汇报","h2":"达成率分布与断层","sub":"7 人落在「严重」档（<20%）；头部与长尾断层显著","ds":"","meta":"","eyebrow":"","tocg":"","h1":"","notes":["头部最高 3 人（路要峰 76.2%、刘虹晶 71.8%、李江辉 62.4%）与尾部最低 3 人（王诗香 3.5%、黄建华 2.5%、韩远怀 1.2%）相差约 63.5 倍； 生命科学线 8 人半年度合计实际仅 33.7 万，而该线年度目标 900 万。"],"kpis":[],"tables":[],"ids":{"chTier":"健康 ≥70%2(9.1%)关注 50–70%1(4.5%)警示 20–50%9(40.9%)严重 <20%7(31.8%)原表未填3(13.6%)","chRank":"路要峰76.2%刘虹晶71.8%李江辉62.4%杨天雄43.1%宋学伟42.3%刘欣39.8%冯贤平35.0%刘新元32.5%陈溪子31.9%黄文才26.9%林潇24.3%赵云浩20.9%……0.0%徐卓凡8.3%吴云5.3%王诗香3.5%黄建华2.5%韩远怀1.2%刘斌0.0%袁殿果0.0%侯海瑜0.0%"}},{"i":7,"t":"Q3 飞书活动与客诉","kicker":"","h2":"Q3 飞书活动与客诉","sub":"","ds":"5,584 条活动 / 24 人；活动量不等于产出","meta":"","eyebrow":"","tocg":"","h1":"","notes":[],"kpis":[],"tables":[],"ids":{}},{"i":8,"t":"② 活动量总览","kicker":"② Q3 飞书活动","h2":"活动量总览","sub":"5584 条 / 24 人；按月看 7→9 月逐月上升","ds":"","meta":"","eyebrow":"","tocg":"","h1":"","notes":["数据源：飞书活动导出（Q3 全量 5584 条，逐条含 work_item_id，可点开原文）。"],"kpis":[],"tables":[{"h3":"全部 24 人活动量明细","rows":[["#","销售","合计","7月","8月","9月"],["1","侯海瑜","425","108","162","155"],["2","叶信福","424","125","153","146"],["3","王诗香","423","87","149","187"],["4","袁殿果","422","115","152","155"],["5","黄建华","386","109","148","129"],["6","刘斌","361","107","143","111"],["7","刘虹晶","344","101","123","120"],["8","陈彩红","288","0","129","159"],["9","宋学伟","271","74","103","94"],["10","林潇","245","72","90","83"],["11","冯贤平","244","56","86","102"],["12","赵云浩","241","73","80","88"],["13","陈溪子","236","61","84","91"],["14","李江辉","227","67","71","89"],["15","黄文才","223","60","76","87"],["16","杨天雄","195","51","69","75"],["17","张文蝶","193","55","63","75"],["18","路要峰","173","50","63","60"],["19","徐卓凡","129","46","43","40"],["20","张立娅","44","44","0","0"],["21","吴云","31","10","11","10"],["22","韩远怀","20","4","11","5"],["23","刘新元","20","0","7","13"],["24","刘子研","19","0","0","19"]]}],"ids":{"chActMonth":"147507月201608月209309月","chActSales":"侯海瑜425.0叶信福424.0王诗香423.0袁殿果422.0黄建华386.0刘斌361.0刘虹晶344.0陈彩红288.0宋学伟271.0林潇245.0冯贤平244.0赵云浩241.0","tbActSales":"1侯海瑜4251081621552叶信福4241251531463王诗香423871491874袁殿果4221151521555黄建华3861091481296刘斌3611071431117刘虹晶3441011231208陈彩红28801291599宋学伟271741039410林潇24572908311冯贤平244568610212赵云浩24173808813陈溪子23661849114李江辉22767718915黄文才22360768716杨天雄19551697517张文蝶19355637518路要峰17350636019徐卓凡12946434020张立娅44440021吴云3110111022韩远怀20411523刘新元20071324刘子研190019"}},{"i":9,"t":"② 活动量与产出匹配","kicker":"② Q3 飞书活动","h2":"活动量与产出匹配度","sub":"把「活动条数」与「ERP 2026 YTD 销售额」并表 —— 活动量不等于产出","ds":"","meta":"","eyebrow":"","tocg":"","h1":"","notes":["重点判读：活动条数 TOP 6 中有 5 人来自生命科学（科研）线，但其 ERP YTD 产出与活动量严重不匹配（如 的「万元/百条活动」均低于 3）。「活动量」是过程指标，不能代替结果指标；建议把科研线的活动质量（有效客户数、测试转化）单独设指标。"],"kpis":[],"tables":[{"h3":"","rows":[["#","销售","Q3 活动(条)","ERP YTD(万)","万/百条","判读"],["1","侯海瑜","425","—","—","无出单"],["2","叶信福","424","—","—","无出单"],["3","王诗香","423","—","—","无出单"],["4","袁殿果","422","—","—","无出单"],["5","黄建华","386","—","—","无出单"],["6","刘斌","361","—","—","无出单"],["7","刘虹晶","344","397.2","115.47","匹配"],["8","陈彩红","288","—","—","无出单"],["9","宋学伟","271","200.4","73.95","匹配"],["10","林潇","245","106.8","43.59","匹配"],["11","冯贤平","244","126.9","52.01","匹配"],["12","赵云浩","241","462.7","191.99","匹配"],["13","陈溪子","236","462.1","195.81","匹配"],["14","李江辉","227","218.3","96.17","匹配"],["15","黄文才","223","223.8","100.36","匹配"],["16","杨天雄","195","175.5","90.00","匹配"],["17","张文蝶","193","31.8","16.48","匹配"],["18","路要峰","173","278.8","161.16","匹配"],["19","徐卓凡","129","—","—","无出单"],["20","张立娅","44","—","—","无出单"],["21","吴云","31","—","—","无出单"],["22","韩远怀","20","—","—","无出单"],["23","刘新元","20","132.5","662.50","匹配"],["24","刘子研","19","511.6","2692.63","匹配"]]}],"ids":{"tbActOut":"1侯海瑜425——无出单2叶信福424——无出单3王诗香423——无出单4袁殿果422——无出单5黄建华386——无出单6刘斌361——无出单7刘虹晶344397.2115.47匹配8陈彩红288——无出单9宋学伟271200.473.95匹配10林潇245106.843.59匹配11冯贤平244126.952.01匹配12赵云浩241462.7191.99匹配13陈溪子236462.1195.81匹配14李江辉227218.396.17匹配15黄文才223223.8100.36匹配16杨天雄195175.590.00匹配17张文蝶19331.816.48匹配18路要峰173278.8161.16匹配19徐卓凡129——无出单20张立娅44——无出单21吴云31——无出单22韩远怀20——无出单23刘新元20132.5662.50匹配24刘子研19511.62692.63匹配","actOutNote":"重点判读：活动条数 TOP 6 中有 5 人来自生命科学（科研）线，但其 ERP YTD 产出与活动量严重不匹配（如 的「万元/百条活动」均低于 3）。「活动量」是过程指标，不能代替结果指标；建议把科研线的活动质量（有效客户数、测试转化）单独设指标。"}},{"i":10,"t":"② 高频客户 TOP","kicker":"② Q3 飞书活动","h2":"各人高频客户 TOP 5","sub":"活动密度反映客户渗透深度；科研线为课题组/高校，诊断线为公司客户","ds":"","meta":"","eyebrow":"","tocg":"","h1":"","notes":["仅统计 Q3 该销售名下活动记录中出现次数最多的客户；同名客户的集团/主体差异未做合并。"],"kpis":[],"tables":[{"h3":"","rows":[["#","销售","高频客户（TOP 5，括号为活动数）"],["1","王诗香","华南农业大学-广东 (380) › 暨南大学-广东 (11) › 北京师范大学-广东 (8) › 中山大学-广东 (8) › 南方科技大学-广东 (3)"],["2","刘斌","暨南大学-广东 (358) › 河源市深河人民医院-广东 (1) › 中山火炬开发区人民医院-广东 (1)"],["3","陈彩红","南方医科大学-广东 (287) › 南方医科大学南方医院-广东 (1)"],["4","侯海瑜","浙江大学-浙江 (232) › 杭州师范大学-浙江 (99) › 浙江省人民医院-浙江 (90) › 杭州医学院-浙江 (4)"],["5","黄建华","中山大学附属第一医院-广东 (215) › 中山大学-广东 (81) › 中山大学附属口腔医院-广东 (79) › 广东省人民医院-广东 (8) › 广东药科大学-广东 (3)"],["6","袁殿果","温州医科大学-浙江 (197) › 浙江大学-浙江 (60) › 中国水稻研究所-浙江 (60) › 国科大杭州高等研究院-浙江 (54) › 浙江理工大学-浙江 (43)"],["7","叶信福","浙江农林大学-浙江 (167) › 浙江大学-浙江 (166) › 浙江中医药大学-浙江 (91)"],["8","赵云浩","圣湘生物科技股份有限公司 (102) › 广州万孚生物技术股份有限公司 (40) › 郑州纳克智造生物科技有限公司 (25) › 郑州中道生物技术有限公司 (14) › 武汉明德生物科技股份有限公司 (11)"],["9","宋学伟","江苏宏微特斯医药科技有限公司 (48) › 英科新创（苏州）生物科技有限公司 (32) › 江苏默乐生物科技股份有限公司 (23) › 翊新诊断技术（苏州）有限公司 (12) › 南京英诺唯真生物科技有限公司 (10)"],["10","林潇","深圳市亿立方生物技术有限公司 (44) › 壹宏（深圳）基因有限公司 (30) › 深圳市积光生物科技有限公司 (19) › 深圳市尚维高科有限公司 (15) › 世通兰达（深圳）生物科技发展有限公司 (14)"],["11","刘虹晶","山东攸诺医学科技有限公司 (37) › 青岛嘉智生物技术有限公司 (28) › 瑞吉明（山东）生物科技有限公司 (17) › 丹娜（天津）生物科技股份有限公司 (14) › 保定佳瑞源生物芯片有限公司 (14)"],["12","冯贤平","北京卓诚惠生生物科技股份有限公司 (30) › 北京万泰生物药业股份有限公司 (13) › 新羿制造科技（北京）有限公司 (12) › 思纳福（北京）医疗科技有限公司 (12) › 北京华大吉比爱生物技术有限公司 (9)"],["13","吴云","浙江大学-浙江 (25) › 温州医科大学-浙江 (3) › 杭州泽衡生物科技有限公司-浙江 (1) › 浙江中医药大学-浙江 (1) › 宁波东方理工大学-浙江 (1)"],["14","黄文才","星阵（广州）基因科技有限公司 (22) › 广州悦洋生物技术有限公司 (12) › 珠海市银科医学工程股份有限公司 (12) › 广州国家实验室 (11) › 中科绿康生物科技（珠海）有限公司 (9)"],["15","路要峰","上海伯杰医疗科技股份有限公司 (21) › 上海万子健生物科技有限公司 (11) › 沈阳市戎沈生物科技有限公司 (11) › 上海欧易生物医学科技有限公司 (10) › 上海汇吉生物技术有限公司 (10)"],["16","李江辉","湖南圣测生物科技有限公司 (18) › 武汉正大康瑞生物科技有限公司 (15) › 湖南冠牧生物科技有限公司 (15) › 武汉友芝友医疗科技股份有限公司 (14) › 武汉贝纳医学科技有限公司 (9)"],["17","陈溪子","深圳迈瑞生物医疗电子股份有限公司 (16) › 广州达安基因股份有限公司 (16) › 深圳市臻惠医疗科技有限责任公司 (15) › 深圳市亚辉龙生物科技股份有限公司 (15) › 广州易安生物技术有限公司 (13)"],["18","徐卓凡","江苏硕世生物科技股份有限公司 (16) › 上海科技大学 (11) › 上海透景生命科技股份有限公司 (7) › 上海之江生物科技股份有限公司 (3) › 上海芯超生物科技有限公司 (3)"],["19","张文蝶","币冠（上海）生物科技有限公司 (15) › 上海美吉生物医药科技有限公司 (14) › 上海快灵生物科技有限公司 (13) › 重庆巴斯德生物医药科技有限公司 (12) › 上海纳全生物医学科技有限公司 (11)"],["20","杨天雄","杭州逸检科技有限公司 (13) › 杭州比格飞序生物科技有限公司 (12) › 杭州岳晨医药科技有限公司 (12) › 杭州博日科技股份有限公司 (11) › 杭州优思达生物技术股份有限公司 (8)"],["21","张立娅","珠海丽珠试剂股份有限公司 (12) › 苏州天隆生物科技有限公司 (11) › 杭州丹威生物科技有限公司 (7) › 西安佰奥莱博生物科技有限公司 (7) › 复星诊断科技（上海）有限公司 (2)"],["22","韩远怀","中山大学-广东 (7) › 广州瑞扬生物科技有限公司-广东 (4) › 广东省人民医院-广东 (3) › 广东医科大学附属第二医院-广东 (1) › 广州中医药大学-广东 (1)"],["23","刘新元","苏州天隆生物科技有限公司 (7) › 杭州丹威生物科技有限公司 (5) › 深圳市新产业生物医学工程股份有限公司 (3) › 宁波海尔施基因科技股份有限公司 (2) › 西安佰奥莱博生物科技有限公司 (1)"],["24","刘子研","复星诊断科技（上海）有限公司 (3) › 苏州天隆生物科技有限公司 (3) › 杭州迪安生物技术有限公司 (3) › 深圳市新产业生物医学工程股份有限公司 (2) › 杭州丹威生物科技有限公司 (2)"]]}],"ids":{"tbActCust":"1王诗香华南农业大学-广东 (380) › 暨南大学-广东 (11) › 北京师范大学-广东 (8) › 中山大学-广东 (8) › 南方科技大学-广东 (3)2刘斌暨南大学-广东 (358) › 河源市深河人民医院-广东 (1) › 中山火炬开发区人民医院-广东 (1)3陈彩红南方医科大学-广东 (287) › 南方医科大学南方医院-广东 (1)4侯海瑜浙江大学-浙江 (232) › 杭州师范大学-浙江 (99) › 浙江省人民医院-浙江 (90) › 杭州医学院-浙江 (4)5黄建华中山大学附属第一医院-广东 (215) › 中山大学-广东 (81) › 中山大学附属口腔医院-广东 (79) › 广东省人民医院-广东 (8) › 广东药科大学-广东 (3)6袁殿果温州医科大学-浙江 (197) › 浙江大学-浙江 (60) › 中国水稻研究所-浙江 (60) › 国科大杭州高等研究院-浙江 (54) › 浙江理工大学-浙江 (43)7叶信福浙江农林大学-浙江 (167) › 浙江大学-浙江 (166) › 浙江中医药大学-浙江 (91)8赵云浩圣湘生物科技股份有限公司 (102) › 广州万孚生物技术股份有限公司 (40) › 郑州纳克智造生物科技有限公司 (25) › 郑州中道生物技术有限公司 (14) › 武汉明德生物科技股份有限公司 (11)9宋学伟江苏宏微特斯医药科技有限公司 (48) › 英科新创（苏州）生物科技有限公司 (32) › 江苏默乐生物科技股份有限公司 (23) › 翊新诊断技术（苏州）有限公司 (12) › 南京英诺唯真生物科技有限公司 (10)10林潇深圳市亿立方生物技术有限公司 (44) › 壹宏（深圳）基因有限公司 (30) › 深圳市积光生物科技有限公司 (19) › 深圳市尚维高科有限公司 (15) › 世通兰达（深圳）生物科技发展有限公司 (14)11刘虹晶山东攸诺医学科技有限公司 (37) › 青岛嘉智生物技术有限公司 (28) › 瑞吉明（山东）生物科技有限公司 (17) › 丹娜（天津）生物科技股份有限公司 (14) › 保定佳瑞源生物芯片有限公司 (14)12冯贤平北京卓诚惠生生物科技股份有限公司 (30) › 北京万泰生物药业股份有限公司 (13) › 新羿制造科技（北京）有限公司 (12) › 思纳福（北京）医疗科技有限公司 (12) › 北京华大吉比爱生物技术有限公司 (9)13吴云浙江大学-浙江 (25) › 温州医科大学-浙江 (3) › 杭州泽衡生物科技有限公司-浙江 (1) › 浙江中医药大学-浙江 (1) › 宁波东方理工大学-浙江 (1)14黄文才星阵（广州）基因科技有限公司 (22) › 广州悦洋生物技术有限公司 (12) › 珠海市银科医学工程股份有限公司 (12) › 广州国家实验室 (11) › 中科绿康生物科技（珠海）有限公司 (9)15路要峰上海伯杰医疗科技股份有限公司 (21) › 上海万子健生物科技有限公司 (11) › 沈阳市戎沈生物科技有限公司 (11) › 上海欧易生物医学科技有限公司 (10) › 上海汇吉生物技术有限公司 (10)16李江辉湖南圣测生物科技有限公司 (18) › 武汉正大康瑞生物科技有限公司 (15) › 湖南冠牧生物科技有限公司 (15) › 武汉友芝友医疗科技股份有限公司 (14) › 武汉贝纳医学科技有限公司 (9)17陈溪子深圳迈瑞生物医疗电子股份有限公司 (16) › 广州达安基因股份有限公司 (16) › 深圳市臻惠医疗科技有限责任公司 (15) › 深圳市亚辉龙生物科技股份有限公司 (15) › 广州易安生物技术有限公司 (13)18徐卓凡江苏硕世生物科技股份有限公司 (16) › 上海科技大学 (11) › 上海透景生命科技股份有限公司 (7) › 上海之江生物科技股份有限公司 (3) › 上海芯超生物科技有限公司 (3)19张文蝶币冠（上海）生物科技有限公司 (15) › 上海美吉生物医药科技有限公司 (14) › 上海快灵生物科技有限公司 (13) › 重庆巴斯德生物医药科技有限公司 (12) › 上海纳全生物医学科技有限公司 (11)20杨天雄杭州逸检科技有限公司 (13) › 杭州比格飞序生物科技有限公司 (12) › 杭州岳晨医药科技有限公司 (12) › 杭州博日科技股份有限公司 (11) › 杭州优思达生物技术股份有限公司 (8)21张立娅珠海丽珠试剂股份有限公司 (12) › 苏州天隆生物科技有限公司 (11) › 杭州丹威生物科技有限公司 (7) › 西安佰奥莱博生物科技有限公司 (7) › 复星诊断科技（上海）有限公司 (2)22韩远怀中山大学-广东 (7) › 广州瑞扬生物科技有限公司-广东 (4) › 广东省人民医院-广东 (3) › 广东医科大学附属第二医院-广东 (1) › 广州中医药大学-广东 (1)23刘新元苏州天隆生物科技有限公司 (7) › 杭州丹威生物科技有限公司 (5) › 深圳市新产业生物医学工程股份有限公司 (3) › 宁波海尔施基因科技股份有限公司 (2) › 西安佰奥莱博生物科技有限公司 (1)24刘子研复星诊断科技（上海）有限公司 (3) › 苏州天隆生物科技有限公司 (3) › 杭州迪安生物技术有限公司 (3) › 深圳市新产业生物医学工程股份有限公司 (2) › 杭州丹威生物科技有限公司 (2)"}},{"i":11,"t":"关键客诉与风险事项","kicker":"","h2":"关键客诉与风险事项","sub":"","ds":"66 条客诉 · 62 条未闭环 · 高风险账款 12 项","meta":"","eyebrow":"","tocg":"","h1":"","notes":[],"kpis":[],"tables":[],"ids":{}},{"i":12,"t":"③ 客诉全貌","kicker":"③ 关键客诉与风险","h2":"Q3 客诉全貌","sub":"Q3 66 条（飞书全量 362 条）；未闭环 62 条，占 93.9%","ds":"","meta":"","eyebrow":"","tocg":"","h1":"","notes":["紧急度分布：medium 4 条、normal 62 条。 已闭环仅 4 条；未闭环中 P0（大客户区域）26 条、P1（其他区域）36 条 —— 逐条附飞书链接，见下页。"],"kpis":[],"tables":[],"ids":{"chCmpArea":"大客户27(40.9%)销售拓展部34(51.5%)浙江4(6.1%)广东1(1.5%)","chCmpCreator":"赵云浩14.0 条李江辉9.0 条刘新元9.0 条林潇6.0 条刘虹晶5.0 条刘子研4.0 条杨天雄4.0 条陈溪子4.0 条","chCmpStat":"未闭环62(93.9%)已闭环4(6.1%)"}},{"i":13,"t":"③ 未闭环客诉清单","kicker":"③ 关键客诉与风险","h2":"未闭环客诉清单（可点开飞书原文）","sub":"P0 大客户区域 26 条 ｜ P1 其他区域 36 条；按滞留天数降序","ds":"","meta":"","eyebrow":"","tocg":"","h1":"","notes":["链接口径：project.feishu.cn/br-shgl/khts/detail/<id>（客诉字段仅含 id，无直接 URL）。"],"kpis":[],"tables":[{"h3":"","rows":[["级别","悬浮(天)","客诉名称","客户","提报人","区域","链接"],["P1","91","20260702-德诺泰克-FM5144沉淀","潍坊德诺泰克生物科技有限公司","刘虹晶","销售拓展部","飞书 ↗"],["P1","90","20260703-西诺通科-M2181-4-095203包装问题","西诺通科（天津）生物科技有限公司","刘虹晶","销售拓展部","飞书 ↗"],["P1","90","20260703-湖南圣测- AHRM5014体系buffer异常客诉","湖南圣测生物科技有限公司","李江辉","销售拓展部","飞书 ↗"],["P0","86","20260626-天隆-M5244-ZJ4-TP批间差异客诉","苏州天隆生物科技有限公司","刘子研","大客户","飞书 ↗"],["P1","84","20260709-岳晨-FM5181-4-NA-090803 近期新批次在POCT芯片流道汇入后易出气泡","杭州岳晨医药科技有限公司","杨天雄","销售拓展部","飞书 ↗"],["P1","83","20260710-青岛嘉智-M2274-073702单组份-试剂少装","青岛嘉智生物技术有限公司","刘虹晶","销售拓展部","飞书 ↗"],["P0","80","20260713（补）-丽珠试剂-2AM101 配置错误召回换货","珠海丽珠试剂股份有限公司","刘新元","大客户","飞书 ↗"],["P0","79","20260714-天隆-MD2071-2-NA低残留酶有问题客诉","苏州天隆生物科技有限公司","刘子研","大客户","飞书 ↗"],["P1","79","20260714-济南优柯-FHW1007-M01-013401-buffer变色","济南优柯生物技术有限公司","刘虹晶","销售拓展部","飞书 ↗"],["P1","78","20260715-浙江大学-BR1E102 CT值异常","杭州瀚笙生物科技有限公司-浙江","袁殿果","浙江","飞书 ↗"],["P0","77","20260716-PT-MM2274-073702说明书客诉","洛阳普泰生物技术有限公司","赵云浩","大客户","飞书 ↗"],["P1","73","20260720-壹宏-（FM5071，FM5181-4-105903，冻干形态异常）","壹宏（深圳）基因有限公司","林潇","销售拓展部","飞书 ↗"],["P1","66","20260727-湖南国测-非瘟原位冻干粉萎缩客诉","湖南国测生物科技有限公司","李江辉","销售拓展部","飞书 ↗"],["P1","65","20260728-积光-（AS412-9-NA固体析出）","深圳市积光生物科技有限公司","林潇","销售拓展部","飞书 ↗"],["P0","64","20260729-苏州天隆- MD2104-003003-DB","苏州天隆生物科技有限公司","刘新元","大客户","飞书 ↗"],["P1","64","20260729-广州悦洋-MD2104-017801漏液","广州悦洋生物技术有限公司","黄文才","销售拓展部","飞书 ↗"],["P1","64","20260729-广州悦洋-MD2111-DB客诉","广州悦洋生物技术有限公司","黄文才","销售拓展部","飞书 ↗"],["P1","64","20260729-合肥行知-运输过程4天产品质量客诉","合肥行知生物技术有限公司","李江辉","销售拓展部","飞书 ↗"],["P0","56","20260806-杭州丹威-FM5134-DW RnaseP超标退回","杭州丹威生物科技有限公司","刘新元","大客户","飞书 ↗"],["P0","55","20260807-WF-标签错误（FMD5104-000829)","广州万孚生物技术股份有限公司","赵云浩","大客户","飞书 ↗"],["P1","55","20260807-积光-（FMD5084-000903-DB）发错","深圳市积光生物科技有限公司","林潇","销售拓展部","飞书 ↗"],["P1","51","20260811-NBHG- PFHW1007-R02-O25-205503发货数量不足","宁波海关技术中心","杨天雄","销售拓展部","飞书 ↗"],["P0","50","20260812-NK-IME-DR0601-I-W50T退货补流程","郑州纳克智造生物科技有限公司","赵云浩","大客户","飞书 ↗"],["P1","50","20260812-广州悦洋-MD2104-017801漏液","广州悦洋生物技术有限公司","黄文才","销售拓展部","飞书 ↗"],["P1","49","20260813-zyhj-多货号冻干球加速3天萎缩","中元汇吉生物技术股份有限公司","路要峰","销售拓展部","飞书 ↗"],["P0","43","20260819-WF-FE20订单需求变更","广州万孚生物技术股份有限公司","赵云浩","大客户","飞书 ↗"],["P1","42","20260820-SKY-M5244-T4批间差","深圳生科原技术有限公司","陈溪子","销售拓展部","飞书 ↗"],["P1","37","20260825-SKY-M5244-NA-043801-西尼罗河病毒产品阴性翘尾","深圳生科原技术有限公司","陈溪子","销售拓展部","飞书 ↗"],["P0","37","20260825-sztl-FM2181-4下错单","苏州天隆生物科技有限公司","刘新元","大客户","飞书 ↗"],["P0","36","20260826-WF-FE20-50批间差客诉","广州万孚生物技术股份有限公司","赵云浩","大客户","飞书 ↗"],["P0","35","20260827-SX-FE16-NA-50污染客诉","圣湘生物科技股份有限公司","赵云浩","大客户","飞书 ↗"],["P1","35","20260827-湖南冠牧-E20内包材漏液","湖南冠牧生物科技有限公司","李江辉","销售拓展部","飞书 ↗"],["P1","30","20260901-奥斯卡-（M5244-T4）发错货","深圳市奥斯卡动物医学科技有限公司","林潇","销售拓展部","飞书 ↗"],["P1","29","20260902-壹宏-（FMD5104-000830配AS212-9-T1）冻干品失效","壹宏（深圳）基因有限公司","林潇","销售拓展部","飞书 ↗"],["P1","27","20260904-丹娜-FMD5104-014405-DB以及保护剂退换货","丹娜（天津）生物科技股份有限公司","刘虹晶","销售拓展部","飞书 ↗"],["P1","24","20260907-湖南圣测-AHRM5014瓶间性能差异（内标质粒CT差异大）","湖南圣测生物科技有限公司","李江辉","销售拓展部","飞书 ↗"],["P1","24","20260907-武汉友芝友-E07热稳定性不合格","武汉友芝友医疗科技股份有限公司","李江辉","销售拓展部","飞书 ↗"],["P0","22","20260909-SX-FM3181-4-NA-014402-5P性能异常","圣湘生物科技股份有限公司","赵云浩","大客户","飞书 ↗"],["P0","17","20260914-SZTL-MD2104-003006-DB-37度加速3天荧光增量骤降","苏州天隆生物科技有限公司","刘新元","大客户","飞书 ↗"],["P0","16","20260915-NK-冻干客诉","郑州纳克智造生物科技有限公司","赵云浩","大客户","飞书 ↗"],["P0","14","20260917-MD-FMD5104-000829人源污染","武汉明德生物科技股份有限公司","赵云浩","大客户","飞书 ↗"],["P0","13","20260918-PT-MD2104-092401批内差","洛阳普泰生物技术有限公司","赵云浩","大客户","飞书 ↗"],["P1","11","20260920YKXC-FMD6104-020322-1酶检测HIV靶标NTC起线","英科新创（厦门）科技股份有限公司","宋学伟","销售拓展部","飞书 ↗"],["P0","10","20260921-XCXY-FHW1007-P01-064806批间差","许昌学院","赵云浩","大客户","飞书 ↗"],["P1","10","20260919-安徽安龙基因-M218-4-246602无扩增曲线","安徽安龙基因科技有限公司","李江辉","销售拓展部","飞书 ↗"],["P0","10","20260921-SX-FE16-50换货","圣湘生物科技股份有限公司","赵云浩","大客户","飞书 ↗"],["P0","9","20260922-LZSJ-BTE-8耗材装液后6.9%概率浑浊","珠海丽珠试剂股份有限公司","刘新元","大客户","飞书 ↗"],["P1","8","20260923-叶洁-BR4C333-01","南方医科大学-广东","陈彩红","广东","飞书 ↗"],["P1","8","20260923-壹宏-冻干品性能下降","壹宏（深圳）基因有限公司","林潇","销售拓展部","飞书 ↗"],["P0","8","20260923-丽珠试剂-2FM091曲线异常客诉","珠海丽珠试剂股份有限公司","刘子研","大客户","飞书 ↗"],["P1","8","20260923-温州医科大学-BR1E102-42-试剂发错","温州医科大学-浙江","袁殿果","浙江","飞书 ↗"],["P0","7","20260921-LZSJ-CM-8plus离心不转","珠海丽珠试剂股份有限公司","刘新元","大客户","飞书 ↗"],["P1","7","20260924-E02-019101-扩增性能批间差","广州湾区生物科技有限公司","陈溪子","销售拓展部","飞书 ↗"],["P1","7","20260924-睿丰康-M8254大肠质检不合格","睿丰康生物医药科技（浙江）有限公司","杨天雄","销售拓展部","飞书 ↗"],["P1","3","20260923-武汉友芝友-E07热稳定性批间差2次售后","武汉友芝友医疗科技股份有限公司","李江辉","销售拓展部","飞书 ↗"],["P1","3","20260922-湖南冠牧-E20内包材漏液","湖南冠牧生物科技有限公司","李江辉","销售拓展部","飞书 ↗"],["P0","3","20260928-XC-磁珠法病毒核酸提取试剂盒Ⅰ客诉","河南蓄诚生物科技有限公司","赵云浩","大客户","飞书 ↗"],["P1","3","9月28日–沈万华课题组-BR1D303-01-BR1C102-02-BR1D201-01室温存放客诉","杭州师范大学-浙江","侯海瑜","浙江","飞书 ↗"],["P1","2","20260929-BGFX- 125项目的管7和管8液体和冻干均不合格","杭州比格飞序生物科技有限公司","杨天雄","销售拓展部","飞书 ↗"],["P0","2","20260929-NK-TZH02-129502-DG-O25污染","郑州纳克智造生物科技有限公司","赵云浩","大客户","飞书 ↗"],["P0","2","20260924-LZSJ-FMD5104-000701-TP（冻干模拟物料）因项目暂停退货","珠海丽珠试剂股份有限公司","刘新元","大客户","飞书 ↗"],["P0","1","20260928-XAHW-M5244-043801到货地址错误未及时入库需换货","西安华伟科技有限公司","刘新元","大客户","飞书 ↗"]]}],"ids":{"tbCmpOpen":"P19120260702-德诺泰克-FM5144沉淀潍坊德诺泰克生物科技有限公司刘虹晶销售拓展部飞书 ↗P19020260703-西诺通科-M2181-4-095203包装问题西诺通科（天津）生物科技有限公司刘虹晶销售拓展部飞书 ↗P19020260703-湖南圣测- AHRM5014体系buffer异常客诉湖南圣测生物科技有限公司李江辉销售拓展部飞书 ↗P08620260626-天隆-M5244-ZJ4-TP批间差异客诉苏州天隆生物科技有限公司刘子研大客户飞书 ↗P18420260709-岳晨-FM5181-4-NA-090803 近期新批次在POCT芯片流道汇入后易出气泡杭州岳晨医药科技有限公司杨天雄销售拓展部飞书 ↗P18320260710-青岛嘉智-M2274-073702单组份-试剂少装青岛嘉智生物技术有限公司刘虹晶销售拓展部飞书 ↗P08020260713（补）-丽珠试剂-2AM101 配置错误召回换货珠海丽珠试剂股份有限公司刘新元大客户飞书 ↗P07920260714-天隆-MD2071-2-NA低残留酶有问题客诉苏州天隆生物科技有限公司刘子研大客户飞书 ↗P17920260714-济南优柯-FHW1007-M01-013401-buffer变色济南优柯生物技术有限公司刘虹晶销售拓展部飞书 ↗P17820260715-浙江大学-BR1E102 CT值异常杭州瀚笙生物科技有限公司-浙江袁殿果浙江飞书 ↗P07720260716-PT-MM2274-073702说明书客诉洛阳普泰生物技术有限公司赵云浩大客户飞书 ↗P17320260720-壹宏-（FM5071，FM5181-4-105903，冻干形态异常）壹宏（深圳）基因有限公司林潇销售拓展部飞书 ↗P16620260727-湖南国测-非瘟原位冻干粉萎缩客诉湖南国测生物科技有限公司李江辉销售拓展部飞书 ↗P16520260728-积光-（AS412-9-NA固体析出）深圳市积光生物科技有限公司林潇销售拓展部飞书 ↗P06420260729-苏州天隆- MD2104-003003-DB苏州天隆生物科技有限公司刘新元大客户飞书 ↗P16420260729-广州悦洋-MD2104-017801漏液广州悦洋生物技术有限公司黄文才销售拓展部飞书 ↗P16420260729-广州悦洋-MD2111-DB客诉广州悦洋生物技术有限公司黄文才销售拓展部飞书 ↗P16420260729-合肥行知-运输过程4天产品质量客诉合肥行知生物技术有限公司李江辉销售拓展部飞书 ↗P05620260806-杭州丹威-FM5134-DW RnaseP超标退回杭州丹威生物科技有限公司刘新元大客户飞书 ↗P05520260807-WF-标签错误（FMD5104-000829)广州万孚生物技术股份有限公司赵云浩大客户飞书 ↗P15520260807-积光-（FMD5084-000903-DB）发错深圳市积光生物科技有限公司林潇销售拓展部飞书 ↗P15120260811-NBHG- PFHW1007-R02-O25-205503发货数量不足宁波海关技术中心杨天雄销售拓展部飞书 ↗P05020260812-NK-IME-DR0601-I-W50T退货补流程郑州纳克智造生物科技有限公司赵云浩大客户飞书 ↗P15020260812-广州悦洋-MD2104-017801漏液广州悦洋生物技术有限公司黄文才销售拓展部飞书 ↗P14920260813-zyhj-多货号冻干球加速3天萎缩中元汇吉生物技术股份有限公司路要峰销售拓展部飞书 ↗P04320260819-WF-FE20订单需求变更广州万孚生物技术股份有限公司赵云浩大客户飞书 ↗P14220260820-SKY-M5244-T4批间差深圳生科原技术有限公司陈溪子销售拓展部飞书 ↗P13720260825-SKY-M5244-NA-043801-西尼罗河病毒产品阴性翘尾深圳生科原技术有限公司陈溪子销售拓展部飞书 ↗P03720260825-sztl-FM2181-4下错单苏州天隆生物科技有限公司刘新元大客户飞书 ↗P03620260826-WF-FE20-50批间差客诉广州万孚生物技术股份有限公司赵云浩大客户飞书 ↗P03520260827-SX-FE16-NA-50污染客诉圣湘生物科技股份有限公司赵云浩大客户飞书 ↗P13520260827-湖南冠牧-E20内包材漏液湖南冠牧生物科技有限公司李江辉销售拓展部飞书 ↗P13020260901-奥斯卡-（M5244-T4）发错货深圳市奥斯卡动物医学科技有限公司林潇销售拓展部飞书 ↗P12920260902-壹宏-（FMD5104-000830配AS212-9-T1）冻干品失效壹宏（深圳）基因有限公司林潇销售拓展部飞书 ↗P12720260904-丹娜-FMD5104-014405-DB以及保护剂退换货丹娜（天津）生物科技股份有限公司刘虹晶销售拓展部飞书 ↗P12420260907-湖南圣测-AHRM5014瓶间性能差异（内标质粒CT差异大）湖南圣测生物科技有限公司李江辉销售拓展部飞书 ↗P12420260907-武汉友芝友-E07热稳定性不合格武汉友芝友医疗科技股份有限公司李江辉销售拓展部飞书 ↗P02220260909-SX-FM3181-4-NA-014402-5P性能异常圣湘生物科技股份有限公司赵云浩大客户飞书 ↗P01720260914-SZTL-MD2104-003006-DB-37度加速3天荧光增量骤降苏州天隆生物科技有限公司刘新元大客户飞书 ↗P01620260915-NK-冻干客诉郑州纳克智造生物科技有限公司赵云浩大客户飞书 ↗P01420260917-MD-FMD5104-000829人源污染武汉明德生物科技股份有限公司赵云浩大客户飞书 ↗P01320260918-PT-MD2104-092401批内差洛阳普泰生物技术有限公司赵云浩大客户飞书 ↗P11120260920YKXC-FMD6104-020322-1酶检测HIV靶标NTC起线英科新创（厦门）科技股份有限公司宋学伟销售拓展部飞书 ↗P01020260921-XCXY-FHW1007-P01-064806批间差许昌学院赵云浩大客户飞书 ↗P11020260919-安徽安龙基因-M218-4-246602无扩增曲线安徽安龙基因科技有限公司李江辉销售拓展部飞书 ↗P01020260921-SX-FE16-50换货圣湘生物科技股份有限公司赵云浩大客户飞书 ↗P0920260922-LZSJ-BTE-8耗材装液后6.9%概率浑浊珠海丽珠试剂股份有限公司刘新元大客户飞书 ↗P1820260923-叶洁-BR4C333-01南方医科大学-广东陈彩红广东飞书 ↗P1820260923-壹宏-冻干品性能下降壹宏（深圳）基因有限公司林潇销售拓展部飞书 ↗P0820260923-丽珠试剂-2FM091曲线异常客诉珠海丽珠试剂股份有限公司刘子研大客户飞书 ↗P1820260923-温州医科大学-BR1E102-42-试剂发错温州医科大学-浙江袁殿果浙江飞书 ↗P0720260921-LZSJ-CM-8plus离心不转珠海丽珠试剂股份有限公司刘新元大客户飞书 ↗P1720260924-E02-019101-扩增性能批间差广州湾区生物科技有限公司陈溪子销售拓展部飞书 ↗P1720260924-睿丰康-M8254大肠质检不合格睿丰康生物医药科技（浙江）有限公司杨天雄销售拓展部飞书 ↗P1320260923-武汉友芝友-E07热稳定性批间差2次售后武汉友芝友医疗科技股份有限公司李江辉销售拓展部飞书 ↗P1320260922-湖南冠牧-E20内包材漏液湖南冠牧生物科技有限公司李江辉销售拓展部飞书 ↗P0320260928-XC-磁珠法病毒核酸提取试剂盒Ⅰ客诉河南蓄诚生物科技有限公司赵云浩大客户飞书 ↗P139月28日–沈万华课题组-BR1D303-01-BR1C102-02-BR1D201-01室温存放客诉杭州师范大学-浙江侯海瑜浙江飞书 ↗P1220260929-BGFX- 125项目的管7和管8液体和冻干均不合格杭州比格飞序生物科技有限公司杨天雄销售拓展部飞书 ↗P0220260929-NK-TZH02-129502-DG-O25污染郑州纳克智造生物科技有限公司赵云浩大客户飞书 ↗P0220260924-LZSJ-FMD5104-000701-TP（冻干模拟物料）因项目暂停退货珠海丽珠试剂股份有限公司刘新元大客户飞书 ↗P0120260928-XAHW-M5244-043801到货地址错误未及时入库需换货西安华伟科技有限公司刘新元大客户飞书 ↗"}},{"i":14,"t":"③ 高风险账款","kicker":"③ 关键客诉与风险","h2":"高风险账款 / 客户风险（12 项）","sub":"源自半年度汇报原文；金额与账龄按汇报人自述，未做外部核对","ds":"","meta":"","eyebrow":"","tocg":"","h1":"","notes":["Q3 的客诉与回款是两个互相咬合的问题 —— 客诉不闭环 → 客户压款 → 回款计划落空（李江辉 7 月回款计划 26.7 万、实际累计回款 0）。"],"kpis":[],"tables":[{"h3":"","rows":[["风险等级","客户","金额","逾期/账龄","说明与措施","来源"],["🔴 极高","郑州中道生物","38,980.8 元","账龄 365 天以上（逾期 734–895 天）","「财务比较难沟通，需线下沟通跟进」——全公司最老账款","赵云浩"],["🔴 极高","北京隆格基因","10,000 元","逾期 172 天","占总逾期 41%，客户经营稳定性不好；出具催款函 + 面谈 + 暂停供货","冯贤平"],["🔴 极高","深圳市芯思微生物","128,000 元","逾期","采购需预付款且需支付同等金额历史账款","林潇"],["🔴 极高","李江辉 名下合计","477,785 元","60天以上 318,980 元（66.76%）","7 月回款计划 267,230 元，实际累计回款 0；90% 集中在湖南冠牧","李江辉"],["🔴 极高","湖南冠牧生物","429,400 元","12 笔，多为 91–180 天","「季度回款周期」；7 月计划含 3 万元","李江辉"],["🔴 极高","圣湘体系","约 517,500 元","0–30 至 181–365 天","含单笔 28 万（逾期 34 天）；「采购比较难沟通，需线下沟通跟进」","赵云浩"],["🟠 高","武汉明德生物","156,811.6 元","14 笔，91–180 天为主","「客户财务会卡付款，需跟进财务沟通」","赵云浩"],["🟠 高","杭州逸检","233,528 元","约 140 天","终端多为机构、审批繁琐（单张发票不超 1 万）；风险低但客户现金流不足","杨天雄"],["🟠 高","睿丰康","144,600 元","约 60 天","因 M8254 客诉直接压制回款；需换货后才能谈回款","杨天雄"],["🟠 高","深圳澳东检验检测","39,000 元","逾期","已发律师函；客户被瀚海低价抢走，实际性能不如我方","林潇"],["🟠 高","聚致","84,004.2 元","约 70 天","领导拉长账期，风险不高但需逐一安排","杨天雄"],["🟡 中","武汉尚睿生物","15,520 元","136/131/123/96 天","「回款拖拉」风险中；原动保研发团队已解散（-72%）","李江辉"]]}],"ids":{"tbRisk":"🔴 极高郑州中道生物38,980.8 元账龄 365 天以上（逾期 734–895 天）「财务比较难沟通，需线下沟通跟进」——全公司最老账款赵云浩🔴 极高北京隆格基因10,000 元逾期 172 天占总逾期 41%，客户经营稳定性不好；出具催款函 + 面谈 + 暂停供货冯贤平🔴 极高深圳市芯思微生物128,000 元逾期采购需预付款且需支付同等金额历史账款林潇🔴 极高李江辉 名下合计477,785 元60天以上 318,980 元（66.76%）7 月回款计划 267,230 元，实际累计回款 0；90% 集中在湖南冠牧李江辉🔴 极高湖南冠牧生物429,400 元12 笔，多为 91–180 天「季度回款周期」；7 月计划含 3 万元李江辉🔴 极高圣湘体系约 517,500 元0–30 至 181–365 天含单笔 28 万（逾期 34 天）；「采购比较难沟通，需线下沟通跟进」赵云浩🟠 高武汉明德生物156,811.6 元14 笔，91–180 天为主「客户财务会卡付款，需跟进财务沟通」赵云浩🟠 高杭州逸检233,528 元约 140 天终端多为机构、审批繁琐（单张发票不超 1 万）；风险低但客户现金流不足杨天雄🟠 高睿丰康144,600 元约 60 天因 M8254 客诉直接压制回款；需换货后才能谈回款杨天雄🟠 高深圳澳东检验检测39,000 元逾期已发律师函；客户被瀚海低价抢走，实际性能不如我方林潇🟠 高聚致84,004.2 元约 70 天领导拉长账期，风险不高但需逐一安排杨天雄🟡 中武汉尚睿生物15,520 元136/131/123/96 天「回款拖拉」风险中；原动保研发团队已解散（-72%）李江辉"}},{"i":15,"t":"ERP 同比","kicker":"","h2":"ERP 同比","sub":"","ds":"2026 年 1–9 月 3,443.0 万，同比 +25.2%","meta":"","eyebrow":"","tocg":"","h1":"","notes":[],"kpis":[],"tables":[],"ids":{}},{"i":16,"t":"④ ERP 总量对照","kicker":"④ ERP 同比","h2":"总量对照","sub":"口径：标准销售订单 + 已审核 + 非赠品 + 剔除宝锐系；金额 = 价税合计","ds":"","meta":"","eyebrow":"","tocg":"","h1":"","notes":["✅ 口径自校验通过：本脚本算出的 2025 上半年 1,586.6 万 ≈ 管理版半年报 PPT 的 1,587 万，误差 <0.1%，说明提取口径与管理层一致。"],"kpis":["2026 年 1–9 月（YTD）3,443.0万订单行 6826","2025 年 1–9 月（同期）2,749.3万同比 +25.2%（+693.7 万）","2025 年全年4,181.4万2026 YTD 已达其 82.3%","2024 年全年3,409.5万2025 全年同比 +22.6%"],"tables":[],"ids":{"chErpTotal":"34102024 全年27492025 1–9月41812025 全年34432026 1–9月","chErpChain":"24672024 1–9月27492025 1–9月34432026 1–9月"}},{"i":17,"t":"④ 月度与季度","kicker":"④ ERP 同比","h2":"2026 月度与季度分布","sub":"与 2025 年同期逐月对照；按季度看 Q1→Q3 逐季上升","ds":"","meta":"","eyebrow":"","tocg":"","h1":"","notes":[],"kpis":["Q11112.4万—","Q21156.6万环比 +4.0%","Q31174.0万环比 +1.5%"],"tables":[],"ids":{"chErpMonth":"01月02月03月04月05月06月07月08月09月2025 同期2026"}},{"i":18,"t":"④ 部门达成与缺口","kicker":"④ ERP 同比","h2":"部门达成与 Q4 缺口","sub":"年度目标 大客户 2,650 万 / 销售拓展 3,400 万 / 生命科学 900 万 / 合计 6,950 万","ds":"","meta":"","eyebrow":"","tocg":"","h1":"","notes":["按 1–9 月进度线性外推，全年约 4,590.7 万； 距 6,950 万年度目标缺口 3,507.0 万 → Q4 月均需 1,169.0 万，是 1–9 月月均 382.6 万的 3.06 倍。"],"kpis":[],"tables":[{"h3":"","rows":[["部门","年度目标(万)","2026 YTD(万)","达成率","进度"],["大客户部","2650","1106.8","41.77%",""],["销售拓展部","3400","2296.1","67.53%",""],["生命科学部","900","39.9","4.43%",""],["合计","6950","3443.0","49.54%",""]]}],"ids":{"chErpDept":"大客户部1106.8 万生命科学部39.9 万销售拓展部2296.1 万","chErpQ":"Q11112.4 万Q21156.6 万Q31174.0 万","tbTarget":"大客户部26501106.841.77%销售拓展部34002296.167.53%生命科学部90039.94.43%合计69503443.049.54%"}},{"i":19,"t":"④ 客户 / 销售员排名","kicker":"④ ERP 同比","h2":"客户与销售员排名（2026 YTD）","sub":"客户 TOP 20 ｜ 销售员 TOP 15（万元）","ds":"","meta":"","eyebrow":"","tocg":"","h1":"","notes":["⚠️ 2025 年名册用岗位（大客户1/大客户2）而非姓名，故跨年个人同比只在实名制人员间可比。 ℹ️ 销售员口径：第 1 名刘子研为「大客户1岗」合并口径 —— 已并入黄明月、张立娅两人业绩（大客户1岗交接后按一个人统计）。其金额不可与未合并人员的 YTD 直接横向比较；如需分人明细请另见 ERP 原始归集。"],"kpis":[],"tables":[{"h3":"客户端 TOP 20","rows":[["#","客户","YTD(万)"],["1","珠海丽珠试剂股份有限公司","238.8"],["2","保密客户","185.3"],["3","广州生凌智造科技有限公司","121.1"],["4","深圳生科原技术有限公司","117.3"],["5","广州万孚生物技术股份有限公司","104.9"],["6","湖南圣测生物科技有限公司","104.8"],["7","青岛嘉智生物技术有限公司","97.4"],["8","武汉九泽医疗科技有限公司","94.7"],["9","英科新创（苏州）生物科技有限公司","88.1"],["10","西安华伟科技有限公司","84.3"],["11","圣湘（上海）基因科技有限公司","74.2"],["12","天津知因生物科技有限公司","70.7"],["13","苏州华益美生物科技有限公司","70.0"],["14","圣湘生物科技股份有限公司","66.8"],["15","上海伯杰医疗科技股份有限公司","66.3"],["16","江苏宏微特斯医药科技有限公司","64.1"],["17","北京明日达科技发展有限责任公司","63.3"],["18","珠海赛乐奇生物技术股份有限公司","61.6"],["19","杭州丹威生物科技有限公司","58.8"],["20","湖南冠牧生物科技有限公司","58.3"]]},{"h3":"销售员 TOP 15","rows":[["#","销售","YTD(万)","占比"],["1","刘子研","511.6","14.9%"],["2","赵云浩","462.7","13.4%"],["3","陈溪子","462.1","13.4%"],["4","刘虹晶","397.2","11.5%"],["5","路要峰","278.8","8.1%"],["6","黄文才","223.8","6.5%"],["7","李江辉","218.3","6.3%"],["8","宋学伟","200.4","5.8%"],["9","杨天雄","175.5","5.1%"],["10","刘新元","132.5","3.8%"],["11","冯贤平","126.9","3.7%"],["12","林潇","106.8","3.1%"],["13","任鑫","33.2","1.0%"],["14","张文蝶","31.8","0.9%"],["15","龙友波","21.0","0.6%"]]}],"ids":{"tbTopCust":"1珠海丽珠试剂股份有限公司238.82保密客户185.33广州生凌智造科技有限公司121.14深圳生科原技术有限公司117.35广州万孚生物技术股份有限公司104.96湖南圣测生物科技有限公司104.87青岛嘉智生物技术有限公司97.48武汉九泽医疗科技有限公司94.79英科新创（苏州）生物科技有限公司88.110西安华伟科技有限公司84.311圣湘（上海）基因科技有限公司74.212天津知因生物科技有限公司70.713苏州华益美生物科技有限公司70.014圣湘生物科技股份有限公司66.815上海伯杰医疗科技股份有限公司66.316江苏宏微特斯医药科技有限公司64.117北京明日达科技发展有限责任公司63.318珠海赛乐奇生物技术股份有限公司61.619杭州丹威生物科技有限公司58.820湖南冠牧生物科技有限公司58.3","tbTopSp":"1刘子研511.614.9%2赵云浩462.713.4%3陈溪子462.113.4%4刘虹晶397.211.5%5路要峰278.88.1%6黄文才223.86.5%7李江辉218.36.3%8宋学伟200.45.8%9杨天雄175.55.1%10刘新元132.53.8%11冯贤平126.93.7%12林潇106.83.1%13任鑫33.21.0%14张文蝶31.80.9%15龙友波21.00.6%"}},{"i":20,"t":"④ 客户集中度与同比桥 · 实体 vs 集团口径","kicker":"④ ERP 同比 · 客户结构","h2":"客户集中度与同比桥 · 实体 vs 集团口径","sub":"Q3（7–9 月）合计 1,173.8 万（目标 1,641.8 万 · 达成 71.5% · 同比 +1.0%） ｜ 口径切换：实体口径 集团口径 当前：实体口径","ds":"","meta":"","eyebrow":"","tocg":"","h1":"","notes":["同一客户群：圣湘生物科技股份有限公司 实体口径第 8 名（36.2 万）→ 归集为「圣湘集团」集团口径第 2 名（60.9 万）。Top12 集中度 实体 43.9% → 集团 47.2%；客户数 308 → 298 户。","桥式：1162.5 ⇒ 存量 -63.8 ⇒ 新增 293.1 ⇒ 流失 -218.1 ⇒ 1173.8 万（单位万元；分项逐户加总，末位 ±0.1 舍入）｜ 客户：存量 153 户 · 新增 155 户 · 流失 117 户","口径：hybrid —— 有集团归属的客户并入集团，其余保持独立实体（只合并不丢弃）； 映射源＝官方《诊断原料&生命科学客户清单》→ 数据/diag_mappings.json 的 cust_to_group，Q3 已归集 59 个集团；两口径合计完全相等 （起点/终点均 1,173.8 万）。「保密客户」为 ERP 中真实存在的匿名归集记录，非脱敏错误。"],"kpis":[],"tables":[{"h3":"Q3 客户 Top10 榜单（实体口径）","rows":[["#","客户","Q3(万)","占比"],["1","广州生凌智造科技有限公司","77.8","6.6%"],["2","保密客户","54.8","4.7%"],["3","广州万孚生物技术股份有限公司","50.1","4.3%"],["4","上海伯杰医疗科技股份有限公司","46.0","3.9%"],["5","广州生凌基因科技有限公司","46.0","3.9%"],["6","英科新创（苏州）生物科技有限公司","45.3","3.9%"],["7","深圳生科原技术有限公司","42.9","3.7%"],["8","圣湘生物科技股份有限公司","36.2","3.1%"],["9","天津知因生物科技有限公司","30.9","2.6%"],["10","杭州丹威生物科技有限公司","30.2","2.6%"]]}],"ids":{"chConc":"实体口径 Top1243.9%集团口径 Top1247.2%","chBridge":"起点 · 2025 Q31162.5存量客户增量-63.8新增客户+293.1流失客户-218.1终点 · 2026 Q31173.8桥式：1162.5 ⇒ 存量 -63.8 ⇒ 新增 293.1 ⇒ 流失 -218.1 ⇒ 1173.8 万（单位万元；分项逐户加总，末位 ±0.1 舍入）｜ 客户：存量 153 户 · 新增 155 户 · 流失 117 户","concTip":"同一客户群：圣湘生物科技股份有限公司 实体口径第 8 名（36.2 万）→ 归集为「圣湘集团」集团口径第 2 名（60.9 万）。Top12 集中度 实体 43.9% → 集团 47.2%；客户数 308 → 298 户。","calHint":"当前：实体口径","topTitle":"Q3 客户 Top10 榜单（实体口径）"}},{"i":21,"t":"主要竞争对手","kicker":"","h2":"主要竞争对手","sub":"","ds":"37 个品牌；诺唯赞 631 次提及，断层第一","meta":"","eyebrow":"","tocg":"","h1":"","notes":[],"kpis":[],"tables":[],"ids":{}},{"i":22,"t":"⑤ 竞品热度榜","kicker":"⑤ 主要竞争对手","h2":"竞品提及热度榜","sub":"37 个品牌（Q3 活动命中 + 半年度汇报记录，品牌别名已归一）","ds":"","meta":"","eyebrow":"","tocg":"","h1":"","notes":["诺唯赞 631 次提及，占全部命中 49.6% —— 单一竞品占据一半声量。"],"kpis":[],"tables":[{"h3":"全量 37 品牌（Q3 命中 / 半年报记录）","rows":[["#","品牌","Q3 提及","半年报记录"],["1","诺唯赞","631","59"],["2","翌圣","95","14"],["3","赛默飞","63","3"],["4","全式金","61","7"],["5","雅酶","51","5"],["6","Takara宝生物","43","4"],["7","菲鹏","33","2"],["8","近岸蛋白","33","2"],["9","天根","31","1"],["10","爱博泰克","29","2"],["11","NEB","28","0"],["12","碧云天","27","0"],["13","康为世纪","25","5"],["14","新赛美","18","2"],["15","生工","16","0"],["16","瀚海新酶","14","13"],["17","迈迪安","13","6"],["18","艾科瑞","12","4"],["19","Bio-Rad","11","0"],["20","金诺美","10","1"],["21","Genstar","7","1"],["22","擎科","6","1"],["23","罗氏Roche","6","0"],["24","索莱宝","5","1"],["25","白垩纪","2","1"],["26","tolobio","1","2"],["27","易思得","1","1"],["28","竞品（团购降价）","0","1"],["29","Bioline","0","1"],["30","竞品","0","1"],["31","AG","0","1"],["32","其他厂家","0","1"],["33","凯杰(QIAGEN)","0","1"],["34","进口酶","0","1"],["35","兆维","0","1"],["36","张家口赛诺","0","1"],["37","安徽通用生物","0","1"]]}],"ids":{"chCompHeat":"诺唯赞631.0翌圣95.0赛默飞63.0全式金61.0雅酶51.0Takara宝生物43.0菲鹏33.0近岸蛋白33.0天根31.0爱博泰克29.0NEB28.0碧云天27.0康为世纪25.0新赛美18.0生工16.0瀚海新酶14.0迈迪安13.0艾科瑞12.0","tbComp":"1诺唯赞631592翌圣95143赛默飞6334全式金6175雅酶5156Takara宝生物4347菲鹏3328近岸蛋白3329天根31110爱博泰克29211NEB28012碧云天27013康为世纪25514新赛美18215生工16016瀚海新酶141317迈迪安13618艾科瑞12419Bio-Rad11020金诺美10121Genstar7122擎科6123罗氏Roche6024索莱宝5125白垩纪2126tolobio1227易思得1128竞品（团购降价）0129Bioline0130竞品0131AG0132其他厂家0133凯杰(QIAGEN)0134进口酶0135兆维0136张家口赛诺0137安徽通用生物01"}},{"i":23,"t":"⑤ 诺唯赞深挖","kicker":"⑤ 主要竞争对手","h2":"诺唯赞：从价格战到体系战","sub":"Q3 提及 631 次 ｜ 半年报竞品记录 59 条 ｜ 每条证据附飞书活动链接","ds":"","meta":"2026-09-17 ｜ 宋学伟 ｜ 江苏宏微特斯医药科技有限公司 ｜ 原文 ↗","eyebrow":"","tocg":"","h1":"","notes":["提及高度集中在科研线 5 人 —— 说明科研场景正被诺唯赞体系化覆盖。"],"kpis":[],"tables":[],"ids":{"chInvReaders":"袁殿果105.0 次叶信福83.0 次王诗香78.0 次黄建华69.0 次陈彩红59.0 次刘斌34.0 次侯海瑜30.0 次李江辉25.0 次","invEv":"2026-09-17 ｜ 宋学伟 ｜ 江苏宏微特斯医药科技有限公司 ｜ 原文 ↗疾控方向需求，由于客户终端需求希望有灵敏度和扩增性能更好的体系，所以客户之前使用的诺唯赞的原料不太满足性能要求了，所以在做迭代。该项目涉及单管多重体系，涉及4个通道，多条引探，其中FAM通道有6-7条，FAM通道是一个靶标病毒，但该病毒存在多个变异位点，所以引探数比较多，非特异性起线的通道也是FAM通道，目前匹配的是我…2026-09-29 ｜ 李江辉 ｜ 武汉贝纳医学科技有限公司 ｜ 原文 ↗NGS线下拜访 科研团队研发负责人 邱婷 1、二代测序，客户主要做农口科服项目，20万+T/年检测量，客户与诺唯赞是深度合作状态，投放自动化提取仪、自动化建库仪，以及合作建库试剂模块的形式为长期合作模式，年合作量约100万以上/年，目前基本无需求； 2、三代测序。主要为ONT平台，客户目前主要是需要2个方向…2026-07-30 ｜ 宋学伟 ｜ 苏州阅微基因技术有限公司 ｜ 原文 ↗如沟通，拜访阅微基因摘要： 1.首先于老师反馈他们没听说过货号OK1301，他们用的酶是新海的，但新海生物给于老师这边酶试剂货号信息都是一个代号，官网上查不到的，也没有说明书给他们。所以大概率这个OK1301只是一个代码。 2.于老师透露法医案件上，新海的酶体系确实要贵。客户反馈新海生物法医试剂做了很多年，很有优势…2026-08-06 ｜ 宋学伟 ｜ 苏州为度生物技术有限公司 ｜ 原文 ↗客户主要是做磁珠产品的，他们海外印度有个重要客户主要做分子产品的，如呼吸道、HBV、HPV产品等，主要在用为度的磁珠产品，同时为度也绑定卖些分子扩增试剂给这个印度客户，对为度这边扩增试剂需求量在125万人份，2U/1人份，即taq酶用量500ml.当然，他们这个海外印度客户也有RNA体系项目，但是，RNA体系没有让为度…2026-08-20 ｜ 宋学伟 ｜ 江苏宏微特斯医药科技有限公司 ｜ 原文 ↗1.释放剂直扩可冻干快速-FMD5104-000829 该项目匹配的项目是客户的入院已拿证的呼吸道产品：甲乙流和呼六，其中呼六去年也完成了产品拆分变更。今年开始搭配可冻干的829体系在医院开始推广。预计10月份开始会陆续有采购。 客户近期问题是反馈他们终端客户全复溶829冻干球会有气泡，需要弹几下管子才能消除气泡，…2026-08-25 ｜ 刘虹晶 ｜ 康妍葆（北京）干细胞科技有限公司 ｜ 原文 ↗![](https://project.feishu.cn/goapi/v5/platform/file/stream/download/b2N7g9tT8unAnsays4OitU6_R57lax0ra7uthP6j18GR1vBxyjwo-Rfy8bLBqCiW0dGn7HbBcni9kZ6yMWhz6MtcFR9…2026-07-22 ｜ 路要峰 ｜ 上海伯杰医疗科技股份有限公司 ｜ 原文 ↗张春雷RNA项目：1.报告同步：客户对质检要求为45循环，且无翘尾，全程平线（含不达阈值线） 2.项目背景了解：疫情之前使用进口试剂，疫情期间进行非全预混国产替代，最终只有诺唯赞供货成功；24年Q2季度提出全预混要求，DNA全预混体系送测3款体系，直接有一款适配上了。RNA全预混体系一直在优化，25年底符合要求送测，…2026-09-23 ｜ 杨天雄 ｜ ｜ 原文 ↗NGS拜访 赛图的研发负责人是肖楠，他们这个子公司主要是做空转的芯片和配套试剂，整套的解决方案，我们酶的性能和介绍跟他讲了下，目前他们用的酶主要就是诺唯赞、翌圣和AB，基本都比较稳定，后续他会看下产品目录，找一些可以测试下，但除非价格有优势。…2026-08-10 ｜ 李江辉 ｜ 武汉臻熙医学检验实验室有限公司 ｜ 原文 ↗NGS拜访（三代测序） 研发负责人胡梦竹、研发 王能嵩 1、跟进客户此前6月份DNA超多重项目推荐体系、RNA一管法扩增体系的试剂测试情况。客户回复还未进行测试，主要是试剂此前描述的性能并未达到客户的预期、以及客户目前的项目是有满足需求的体系在使用，客户同意或测试其他家原料供应商主要是看是否有价格上的优势，客户目前原…2026-07-15 ｜ 李江辉 ｜ 武汉科前生物股份有限公司 ｜ 原文 ↗动保试剂研发组 汪洋 1、DNA全预混体系测试反馈，近期是有一个伪狂犬、细小联检的项目在测试，我司M2221-001112体系在单检项目上灵敏度表现的比较好，但是联检就差一点，客户反馈诺唯赞的QV110体系在项目兼容性上会好一点，但是灵敏度不如我司的体系，所以客户想让我司推荐一款体系既能兼顾联检的需求，又能满足灵…"}},{"i":24,"t":"⑤ 竞争态势小结","kicker":"⑤ 主要竞争对手","h2":"竞争态势小结","sub":"每条结论均注明出处，可回溯到飞书活动原文或半年度汇报","ds":"","meta":"","eyebrow":"","tocg":"","h1":"","notes":["承接动作建议：① 建立竞品价格/政策台账（按货号归口，单位不明确一律标注不猜）； ② 科研线做「体系对标」而非单点比价；③ 把测试反馈闭环纳入竞品防守的第一道闸口。"],"kpis":[],"tables":[{"h3":"","rows":[["#","结论","出处"],["1","诺唯赞声量占全部竞品命中的 49.6%，已从单点产品比价升级为「原料+终端试剂+仪器」一体化体系战","Q3 活动 631 次提及 + 半年报竞品记录 59 条"],["2","科研线是被渗透最深的场景：诺唯赞提及者前 5 全部来自生命科学（科研）线","Q3 活动提及者分布（本页左图）"],["3","竞品价格战在诊断线仍在持续，且多为「低价抢单」","半年报竞品板块：瀚海新酶「超低价策略蚕食低端市场」、诺唯赞「华中地区竞争性低价」"],["4","我方仍以单点货号比价应对，缺少体系对标与竞品价格台账","半年报多位销售自述「面对竞品低价谈判被动」「技术壁垒梳理不透彻，只单纯比价」"],["5","客诉与竞品防守互相咬合：性能问题（批间差/污染/沉淀）直接放大竞品可乘之机","Q3 客诉 66 条、未闭环 62 条"]]}],"ids":{"tbCompSummary":"1诺唯赞声量占全部竞品命中的 49.6%，已从单点产品比价升级为「原料+终端试剂+仪器」一体化体系战Q3 活动 631 次提及 + 半年报竞品记录 59 条2科研线是被渗透最深的场景：诺唯赞提及者前 5 全部来自生命科学（科研）线Q3 活动提及者分布（本页左图）3竞品价格战在诊断线仍在持续，且多为「低价抢单」半年报竞品板块：瀚海新酶「超低价策略蚕食低端市场」、诺唯赞「华中地区竞争性低价」4我方仍以单点货号比价应对，缺少体系对标与竞品价格台账半年报多位销售自述「面对竞品低价谈判被动」「技术壁垒梳理不透彻，只单纯比价」5客诉与竞品防守互相咬合：性能问题（批间差/污染/沉淀）直接放大竞品可乘之机Q3 客诉 66 条、未闭环 62 条"}},{"i":25,"t":"结论与缺口","kicker":"CONCLUSION","h2":"结论与数据缺口","sub":"只列可溯源事实；缺口如实标注，不做估算","ds":"","meta":"","eyebrow":"","tocg":"","h1":"","notes":["本页缺口不影响前文结论；前文所有数字均有 JSON 或原始汇报件支撑。"],"kpis":["增长+25.2%同比真实，但增量集中于老客户放量","风险62 条未闭环客诉，直接压制回款","竞争631 次诺唯赞体系化打法已成主要威胁"],"tables":[{"h3":"⚠️ 数据缺口与待补项（不去猜、不估算）","rows":[["#","缺口","现状","补数责任（建议）"],["⚠","原稿勾稽不符 2 人","刘新元：目标 6,950.0 万 / 自报完成率 32.5%，但按已填数复算为 31.12%（反推目标约 6,654.8 万）；吴云：目标 3,000.0 万 / 自报完成率 5.3%，但按已填数复算为 0.53%（反推目标约 302.5 万）","本人 → 直属负责人核对后回填"],["1","生命科学 2 人年度目标 / 完成率","原表为「/」，未填数","刘斌、袁殿果本人 → 生命科学销售部负责人"],["2","回款达成金额","汇报页仅图表，无可核对数字","财务部出明细 → 各汇报人"],["3","2024 年 1–9 月口径","无月度 JSON 明细（MD 已列 2,466.9 万）","销售管理（可补 ERP 导出）"],["4","高风险账款账龄","按汇报人自述，未与财务对账","财务部 × 销售管理"],["5","竞品价格口径","单位不统一（元/支·元/ml·元/T·元/rxn·元/盒）","市场部统一口径后再横向比价"]]}],"ids":{}},{"i":26,"t":"附录 · 数据源与口径","kicker":"APPENDIX","h2":"数据源与口径","sub":"全部结论可回溯；口径与生成时间如下","ds":"","meta":"","eyebrow":"","tocg":"","h1":"","notes":["ERP：标准销售订单 + 非赠品 + 剔宝锐系；金额=价税合计 客诉链接：https://project.feishu.cn/br-shgl/khts/detail/<id> 活动链接：https://project.feishu.cn/baoyu/workitem/<work_item_id> 生成时间：2026-10-01 22:02","本 deck 由生成器从上述 JSON 读取数据绘制，未手工录入任何数字。"],"kpis":[],"tables":[{"h3":"数据源","rows":[["① 半年度汇报","2026年3季度汇报/2026半年度汇报/（34 份）→ 6 子 Agent 结构化提炼"],["② Q3 飞书活动","飞书活动导出 · 5,584 条（Q3 全量）"],["③ 客诉","飞书客诉导出 · 全量 362 条（Q3 66 条）"],["④ ERP","销售订单_20260101-20260930.xlsx ｜ 2025全年订单.xlsx[Sheet1] ｜ 2024全年订单.xlsx[Sheet1]"],["⑤ 竞品","Q3 活动原文命中 + 半年度汇报竞品板块（品牌别名归一）"]]},{"h3":"可复算入口","rows":[["_汇总/人员提炼_H1.json","① 人员结构化数据"],["_汇总/Q3活动客诉竞品.json","② 活动 / 客诉明细"],["_汇总/Q3竞品情报台账.json","⑤ 竞品台账与证据"],["_汇总/erp_yoy.json","④ 四年同期明细"],["_汇总/Q3汇报数据汇总.md","全量文本版（1,762 行）"],["脚本/q3_yoy_compare.py","④ 复算脚本"],["脚本/gen_q3_report_deck.py","本 deck 生成器"]]}],"ids":{}}]